Skip to main content

Table 4 Annual reinfection rate of Helicobacter pylori

From: Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy

  Follow up period No. of patients Mean no. of H. pylori test No. of reinfected patients Patient-years (yr) Annual reinfection rate (%)
  1 ≤ year <2 23 1.39 3 33.08 9.07
E 2 ≤ year <3 18 2.22 3 42.25 7.10
B 3 ≤ year <4 5 2.00 0 16.58 0
M 4 ≤ year <5 8 2.63 0 34.67 0
T 5 ≤ year <6 3 6.00 1 16.58 6.03
  6 ≤ year <7 1 5.00 0 6.5 0
7 ≤ year <8 1 5.00 0 7.5 0
Total 59 2.05 7 157.17 4.45
  1 ≤ year <2 39 1.36 8 54.12 14.78
M 2 ≤ year <3 37 2.05 8 91.75 8.72
E 3 ≤ year <4 30 3.67 1 104.58 0.96
A 4 ≤ year <5 10 3.80 2 43.33 4.62
  Total 116 2.31 19 294.08 6.46
  1. EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d); MEA: moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.).